文献速递妇科产科

心膈角淋巴结对OVHIPEC-1试验中卵巢癌HIPEC患者生存的影响

Influence of cardiophrenic lymph nodes on survival in patients receiving hyperthermic intraperitoneal chemotherapy for ovarian cancer in the OVHIPEC-1 trial.
PubMed 文献 · Gynecol Oncol · 2026-03-28

本研究为OVHIPEC-1试验的事后分析,纳入237例III期卵巢癌患者,由两位放射科专家独立评估基线及反应CT上的心膈角淋巴结(CPLN,短径≥5mm)。44%患者存在至少一个CPLN≥5mm,其新辅助化疗后81%缩小;CPLN阳性与阴性患者总生存相似(HR 0.98,95%CI 0.74-1.30),且未观察到CPLN状态与HIPEC生存获益的交互作用(交互P=0.28)。

要点

  • III期卵巢癌中间减瘤术中,诊断时CPLN短径5-10mm不改变预后判断。
  • CPLN阳性者总生存与阴性者相似,HR 0.98(95%CI 0.74-1.30)。
  • CPLN状态不影响HIPEC生存获益,交互P=0.28。

核心结论

  • 在III期卵巢癌接受中间减瘤术的患者中,诊断时CPLN短径5-10mm未见预后差异或HIPEC疗效降低的证据。

研究设计与样本

  • OVHIPEC-1试验的事后分析,随机分配III期卵巢癌患者至中间减瘤术联合或不联合HIPEC。
  • CPLN短径≥10mm为本研究排除标准;两位放射科专家独立审阅基线及反应CT,识别CPLN≥5mm,分歧共识解决。
  • 237/245例患者有新辅助化疗前CT可评估。

主要发现

  • 105例(44%)存在至少一个CPLN≥5mm。
  • CPLN阳性患者腹膜癌指数评分更高,其他基线特征可比。
  • 新辅助化疗后81%患者CPLN缩小。
  • CPLN阳性与阴性患者总生存相似(HR 0.98,95%CI 0.74-1.30)。
  • 未观察到CPLN状态与HIPEC总生存获益的交互作用(CPLN≥5mm者HR 0.56,95%CI 0.37-0.85;无CPLN者HR 0.78,95%CI 0.54-1.14;交互P=0.28)。

关键数值与推荐

  • CPLN阳性定义为短轴直径≥5mm;短轴直径≥10mm为研究排除标准。
  • 总生存比较HR 0.98(95%CI 0.74-1.30)。
  • HIPEC获益交互分析:CPLN≥5mm者HR 0.56(95%CI 0.37-0.85),无CPLN者HR 0.78(95%CI 0.54-1.14),交互P=0.28。

临床怎么用

  • 对于III期卵巢癌拟行中间减瘤术者,诊断时CPLN短径5-10mm不应作为排除HIPEC或判断预后不良的依据。

局限性

  • 本研究为OVHIPEC-1试验的事后分析。
  • CPLN短径≥10mm患者被排除,结论不适用于该人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Enlarged cardiophrenic lymph nodes (CPLN) are common in patients with advanced ovarian cancer and may indicate stage IV disease. Hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in patients with stage III disease who are eligible for interval cytoreductive surgery (CRS). This OVHIPEC-1 side study investigates the prognostic value of enlarged CPLN and their predictive value for HIPEC benefit. METHODS: We performed a post-hoc analysis of the OVHIPEC-1 trial, which randomized stage III ovarian cancer patients to interval CRS with or without HIPEC. CPLN presence with short-axis diameter (SAD) ≥10 mm was an exclusion criterion for this study. Two expert radiologists independently reviewed baseline and response CT scans from trial participants and identified CPLNs ≥5 mm. Discrepancies were resolved by consensus. RESULTS: CT scans before start of neoadjuvant chemotherapy were available for 237/245 patients; 105 (44%) had at least one CPLN ≥5 mm. CPLN-positive patients had higher peritoneal cancer index scores but otherwise comparable baseline characteristics. CPLN size decreased in 81% after neoadjuvant chemotherapy. Overall survival was similar between patients with and without CPLN (HR 0.98 [95% CI 0.74-1.30]). No interaction between CPLN status and overall survival benefit of HIPEC was observed (HR 0.56 [95% CI 0.37-0.85] with CPLN ≥5 mm versus HR 0.78 [95% CI 0.54-1.14] without; interaction p-value = 0.28). CONCLUSION: In stage III ovarian cancer treated with interval CRS, no evidence was found to suggest a difference in prognostic impact or a reduction in HIPEC efficacy among patients with CPLN SAD 5-10 mm at diagnosis.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Schreuder Goedheijt M, Aronson SL, Sonke GS, et al. Influence of cardiophrenic lymph nodes on survival in patients receiving hyperthermic intraperitoneal chemotherapy for ovarian cancer in the OVHIPEC-1 trial. Gynecol Oncol. 2026. PMID: 41905323. doi:10.1016/j.ygyno.2026.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。